CELC
Price
$9.38
Change
+$0.09 (+0.97%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
347.53M
46 days until earnings call
KANT
Price
$0.35
Change
+$0.02 (+6.06%)
Updated
Apr 2 closing price
Capitalization
4.34M
Ad is loading...

CELC vs KANT

Header iconCELC vs KANT Comparison
Open Charts CELC vs KANTBanner chart's image
Celcuity
Price$9.38
Change+$0.09 (+0.97%)
Volume$6.02K
Capitalization347.53M
Kineta
Price$0.35
Change+$0.02 (+6.06%)
Volume$3.59K
Capitalization4.34M
CELC vs KANT Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. KANT commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and KANT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (CELC: $9.29 vs. KANT: $0.33)
Brand notoriety: CELC and KANT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 434% vs. KANT: 229%
Market capitalization -- CELC: $347.53M vs. KANT: $4.34M
CELC [@Biotechnology] is valued at $347.53M. KANT’s [@Biotechnology] market capitalization is $4.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileKANT’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • KANT’s FA Score: 1 green, 4 red.
According to our system of comparison, KANT is a better buy in the long-term than CELC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 3 TA indicator(s) are bullish.

  • CELC’s TA Score: 3 bullish, 5 bearish.

Price Growth

CELC (@Biotechnology) experienced а -11.61% price change this week, while KANT (@Biotechnology) price change was -15.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

CELC is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($348M) has a higher market cap than KANT($4.34M). KANT YTD gains are higher at: 1.050 vs. CELC (-29.030). KANT has higher annual earnings (EBITDA): -20.45M vs. CELC (-85.45M). CELC has more cash in the bank: 264M vs. KANT (900K). KANT has less debt than CELC: KANT (710K) vs CELC (97.2M). CELC (0) and KANT (0) have equivalent revenues.
CELCKANTCELC / KANT
Capitalization348M4.34M8,018%
EBITDA-85.45M-20.45M418%
Gain YTD-29.0301.050-2,766%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M900K29,333%
Total Debt97.2M710K13,690%
FUNDAMENTALS RATINGS
CELC vs KANT: Fundamental Ratings
CELC
KANT
OUTLOOK RATING
1..100
7871
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6446
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (33) in the null industry is in the same range as CELC (38) in the Miscellaneous Commercial Services industry. This means that KANT’s stock grew similarly to CELC’s over the last 12 months.

CELC's Profit vs Risk Rating (90) in the Miscellaneous Commercial Services industry is in the same range as KANT (100) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

CELC's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as KANT (100) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

KANT's Price Growth Rating (46) in the null industry is in the same range as CELC (64) in the Miscellaneous Commercial Services industry. This means that KANT’s stock grew similarly to CELC’s over the last 12 months.

KANT's P/E Growth Rating (100) in the null industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that KANT’s stock grew similarly to CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELC
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBCCX14.44N/A
N/A
Gabelli Dividend Growth C
FSPHX26.97N/A
N/A
Fidelity Select Health Care
ADGCX14.52N/A
N/A
AB Core Opportunities C
GCVAX23.19N/A
N/A
Goldman Sachs Large Cp Val Insghts A
JSGRX24.62N/A
N/A
JHancock U.S. Growth R2

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with PRME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-8.11%
PRME - CELC
44%
Loosely correlated
-10.30%
ABOS - CELC
43%
Loosely correlated
-2.27%
CRNX - CELC
43%
Loosely correlated
-8.71%
CLDX - CELC
43%
Loosely correlated
-7.16%
VTGN - CELC
41%
Loosely correlated
-6.40%
More

KANT and

Correlation & Price change

A.I.dvisor indicates that over the last year, KANT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KANT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
+7.22%
MDGL - KANT
62%
Loosely correlated
+3.28%
VRPX - KANT
48%
Loosely correlated
-4.69%
SLNO - KANT
45%
Loosely correlated
+7.93%
VKTX - KANT
35%
Loosely correlated
+7.40%
CELC - KANT
34%
Loosely correlated
+0.75%
More